Clinical trials: Hair Diseases
Neoplasms, Alopecia
START: Swiss Taxotere Alopecia Prevention Trial
Primary objective: Rate of complete chemotherapy induced alopecia (WHO grade III or IV, physician grading) Secondary objective: Compliance to scalp cooling procedure Received number of cycles of chemotherapy in each subgroup…
- Trial name
- NCT01008774
- Testing
- Paxman Cooling Machine, Cold Caps
- Where
- Switzerland
- Volunteers
- 239 people
- Sponsor
- Sanofi
Hypotrichosis
Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo
The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost .03% ophthalmic solution) applied to the lateral and medial eyebrows.
- Trial name
- NCT01387906
- Testing
- topical bimatoprost
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Kenneth Beer
Atopic Dermatitis, Dermatology
A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions
The primary goal of the study is to collect standardized patient and clinician reported outcome measures for patients diagnosed with a range of dermatological conditions in an academic clinical practice setting.
- Conditions
- Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata
- Trial name
- ClinPRO-DERM (NCT05084417)
- Testing
- N/A This is an observational study
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- OM1, Inc.
Skin Condition, Eyelash Growth
Eyelash Effect Evaluation for Premium Rejuvenation Eyelash Serum
This study aims to evaluate the efficacy of the Premium Rejuvenation Eyelash Serum on eyelashes and the surrounding periorbital skin.
- Conditions
- Skin Condition, Eyelash Growth, Eyelashes, Skin Health
- Trial name
- NCT07271199
- Testing
- Experimental formula
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hungkuang University
Alopecia, Androgenetic
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
- Trial name
- SCALP2 (NCT05914805)
- Testing
- Clascoterone 5% solution, Vehicle solution
- Where
- 27 sites in United States, Germany and 1 more
- Volunteers
- 762 people
- Sponsor
- Cassiopea SpA
Alopecia Areata
Assessment of Interleukin-15 and Interferon Gamma in Alopecia Areata Before and After Baricitinib.
The primary objective of this study was to evaluate the change in serum interferon gamma and Interleukin-15 levels before and after use of oral drug baricitinib therapy.
- Trial name
- Alopecia (NCT07645430)
- Testing
- Baricitinib 4 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Benha University
Alopecia Totalis/Universalis
Abatacept Costimulatory Blockade in the Treatment of Alopecia Totalis/Universalis
Will Abatacept reduce priming of the hair follicle specific T cells and thereby reduce hair follicle associated infiltration and improve hair growth.
- Trial name
- NCT01314495
- Testing
- Abatacept, Inactive infusion
- Sponsor
- Julian M. Mackay-Wiggan
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)
Evaluate the injections of Ji Gami(TM) and Ji Gami(TM) DO, where cells are expanded ex vivo from scalp, to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451177
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia Areata
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the potential treatment of moderate alopecia areata (AA).
- Trial name
- NCT07733765
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 336 people
- Sponsor
- Pfizer
Androgenic Alopecia, Hair Loss/Baldness
Study to Evaluate Xtressé Gummy Supplement in Men With Androgenic Alopecia
The goal of this study is to determine if Xtresse' gummy is safe and may help regrow hair in men with androgenic alopecia (common pattern hair loss).
- Conditions
- Androgenic Alopecia, Hair Loss/Baldness, Hair Thinning
- Trial name
- NCT07637071
- Testing
- Xtressé Hair Growth Gummies
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Cat Allergy
Exposure Chamber Trial With Cat Immunotherapy
The main purpose of this trial is to investigate if any of three different doses of cat hair immunotherapy is safe for treatment of cat allergic patients.
- Trial name
- NCT00987909
- Testing
- Specific allergen immunotherapy
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- ALK-Abelló A/S
Alopecia Areata
Treatment of Alopecia Areata of the Scalp With Intradermal Injections of Botulinum Toxin
The purpose of this study is to examine prospectively the safety and efficacy of Botulinum Toxin A (Botox) injections in the treatment of patients with alopecia areata of the scalp.
- Trial name
- NCT00408798
- Testing
- Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of British Columbia
Androgenetic Alopecia
Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia
The primary purpose of this study is to assess the safety of performing injections of human autologous hair follicle cells. The study will also measure the impact these injections will have on hair growth.
- Trial name
- NCT01286649
- Testing
- Human autologous hair follicle cells, Cell medium
- Where
- Georgia
- Volunteers
- 19 people
- Sponsor
- TrichoScience Innovations, Inc.
Leukemia
Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.
The goal of this clinical trial is to measure the effects of using a storybook versus standard child life intervention with parents of children newly diagnosed with leukemia on parental stress.
- Trial name
- NCT06360718
- Testing
- "Who is Luke Eemia?" Storybook
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Los Angeles
Squamous Cell Carcinoma (Skin), Squamous Cell Carcinoma in Situ
Hair Regrowth Following Partial Thickness Removal of SSCIS
Participants are being approached to participate in this study because they are undergoing surgery for a skin cancer known as squamous cell carcinoma in situ (SCCIS) on the scalp.
- Conditions
- Squamous Cell Carcinoma (Skin), Squamous Cell Carcinoma in Situ, Alopecia
- Trial name
- NCT07809191
- Testing
- Partial Thickness Excision
- Volunteers
- 15 people
- Sponsor
- The Cooper Health System
Alopecia Areata
Comparative Study Examining the Effectiveness in Use of a DERMOJET and a Normal Syringe Treatment for Patients With Hair Loss - Alopecia Areata
Conventional treatments include the use of steroids applied locally, or injection in to the legion, or oral therapy. Treatment is determined by the severity of the disease. Injection in to the legion can be done in two methods 1.
- Trial name
- NCT01017510
- Testing
- Subcutaneous injection luer syringe, DERMOJET (a syringe without a needle)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Sheba Medical Center
Alopecia Areata
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AA2 (NCT04797650)
- Testing
- CTP-543
- Where
- 63 sites in United States, Canada and 5 more
- Volunteers
- 517 people
- Sponsor
- Concert Pharmaceuticals
Male Pattern Hair Loss, Androgenetic Alopecia
Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
The purpose of this study is to determine the effect of bimatoprost solution on scalp hair growth. Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumigan™) and for thickening of…
- Trial name
- NCT02170662
- Testing
- Bimatoprost
- Volunteers
- 33 people
- Sponsor
- Duke University
Central Centrifugal Cicatricial Alopecia (CCCA)
Tirzepatide for Treatment of CCCA
The goal of this pilot clinical trial is to learn if tirzepatide can treat active central centrifugal cicatricial alopecia (CCCA), a type of permanent scarring hair loss, in adults.
- Trial name
- NCT07734870
- Testing
- Tirzepatide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Alopecia Areata
Topical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata
Alopecia areata (AA) is an autoimmune disorder characterized by non-scarring hair loss of the scalp or any hair-bearing surface. Alopecia areata affects approximately 2% of the general population.
- Trial name
- NCT06399783
- Testing
- Simvastatin, Mometasone Furoate, Fractional CO2 laser
- Where
- Egypt
- Volunteers
- 54 people
- Sponsor
- Assiut University